What is Plus Therapeutics Price-to-Free-Cash-Flow?
As of today (2025-04-13), Plus Therapeutics's share price is $0.75.
Plus Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.84. Hence, Plus Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Plus Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
PSTV's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 28.78 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 51.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 51.70% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 66.70% per year.
During the past 13 years, Plus Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 81.70% per year. The lowest was 4.40% per year. And the median was 50.60% per year.
Plus Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Plus Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Plus Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Plus Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Price-to-Free-Cash-Flow falls into.
Plus Therapeutics's Share Price of today is $0.75. Plus Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Plus Therapeutics (NAS:PSTV) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Plus Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Plus Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PSTV has been successfully added to your 